Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Sector Gamma AS

Sector Gamma AS raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 28.0% in the third quarter, HoldingsChannel.com reports. The fund owned 113,478 shares of the medical equipment provider’s stock after purchasing an additional 24,847 shares during the quarter. Zimmer Biomet comprises approximately 2.8% of Sector Gamma AS’s portfolio, making the stock its 11th biggest position. Sector Gamma AS’s holdings in Zimmer Biomet were worth $11,178,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ZBH. Legacy Wealth Asset Management LLC increased its position in Zimmer Biomet by 2.3% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 4,670 shares of the medical equipment provider’s stock worth $460,000 after purchasing an additional 106 shares in the last quarter. Global Retirement Partners LLC boosted its stake in shares of Zimmer Biomet by 7.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,686 shares of the medical equipment provider’s stock worth $166,000 after purchasing an additional 111 shares during the last quarter. Generali Asset Management SPA SGR grew its holdings in shares of Zimmer Biomet by 0.9% during the third quarter. Generali Asset Management SPA SGR now owns 14,232 shares of the medical equipment provider’s stock worth $1,402,000 after buying an additional 122 shares in the last quarter. Brookstone Capital Management raised its position in shares of Zimmer Biomet by 1.3% in the third quarter. Brookstone Capital Management now owns 9,350 shares of the medical equipment provider’s stock valued at $921,000 after buying an additional 123 shares during the last quarter. Finally, TD Private Client Wealth LLC lifted its stake in shares of Zimmer Biomet by 14.0% during the third quarter. TD Private Client Wealth LLC now owns 999 shares of the medical equipment provider’s stock valued at $98,000 after buying an additional 123 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Down 1.1%

Shares of ZBH opened at $86.55 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $85.33 and a twelve month high of $114.44. The firm has a market capitalization of $17.15 billion, a P/E ratio of 21.42, a price-to-earnings-growth ratio of 2.21 and a beta of 0.62. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59. The stock’s fifty day simple moving average is $91.34 and its 200 day simple moving average is $96.25.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be issued a $0.24 dividend. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Wall Street Analyst Weigh In

Several analysts have commented on ZBH shares. The Goldman Sachs Group cut shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price for the company. in a research note on Friday, January 9th. Citigroup decreased their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a research note on Wednesday, November 5th. Royal Bank Of Canada reduced their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, November 6th. Finally, Barclays lowered their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $107.33.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.